AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Extension Trial of GW 906 in Participants With Essential Hypertension

RecruitingNAAges 18 Years - anyAllShenzhen Salubris Pharmaceuticals Co., Ltd.
💬

In plain words

What the trial is, and whether it could suit you

This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Completed study treatment and the study in accordance with the protocol for GW906 injection. * Willing to participate in the study and provide written informed consent. Exclusion Criteria: * Secondary hypertension. * Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5× upper limit of normal (ULN); Total bilirubin \> 1.5 × ULN; International normalized ratio (INR) \> 2.0; Serum potassium \> 5.0 mmol/L or \< 3.5 mmol/L; eGFR≤30 mL/min/1.73m\^2. * History of any cardiovascular event within 6 months. * Patients with active malignancy or a history of malignancy.
💊

What it tests

  • GW906
📍

Where

1 site
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy